Literature DB >> 15016875

The soluble form of human respiratory syncytial virus attachment protein differs from the membrane-bound form in its oligomeric state but is still capable of binding to cell surface proteoglycans.

Estela Escribano-Romero1, Joanna Rawling, Blanca García-Barreno, José A Melero.   

Abstract

The soluble (Gs) and membrane-bound (Gm) forms of human respiratory syncytial virus (HRSV) attachment protein were purified by immunoaffinity chromatography from cultures of HEp-2 cells infected with vaccinia virus recombinants expressing either protein. Sucrose gradient centrifugation indicated that Gs, which is secreted into the culture medium, remains monomeric, whereas Gm is an oligomer, probably a homotetramer. Nevertheless, Gs was capable of binding to the surface of cells in vitro, as assessed by a flow cytometry-based binding assay. The attachment of Gs to cells was inhibited by previous heparinase treatment of living cells, and Gs did not bind to CHO cell mutants defective in proteoglycan biosynthesis. Thus, Gs, as previously reported for the G protein of intact virions, binds to glycosaminoglycans presented at the cell surface as proteoglycans. Deletion of a previously reported heparin binding domain from Gs protein substantially inhibited its ability to bind to cells, but the remaining level of binding was still sensitive to heparinase treatment, suggesting that other regions of the Gs molecule may contribute to attachment to proteoglycans. The significance of these results for HRSV infection is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016875      PMCID: PMC371076          DOI: 10.1128/jvi.78.7.3524-3532.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase.

Authors:  S Crennell; T Takimoto; A Portner; G Taylor
Journal:  Nat Struct Biol       Date:  2000-11

2.  Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion.

Authors:  L González-Reyes; M B Ruiz-Argüello; B García-Barreno; L Calder; J A López; J P Albar; J J Skehel; D C Wiley; J A Melero
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

3.  Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene.

Authors:  S Techaarpornkul; N Barretto; M E Peeples
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor.

Authors:  J P Langedijk; B L de Groot; H J Berendsen; J T van Oirschot
Journal:  Virology       Date:  1998-04-10       Impact factor: 3.616

5.  Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.

Authors:  J J Gorman; J L McKimm-Breschkin; R S Norton; K J Barnham
Journal:  J Biol Chem       Date:  2001-08-03       Impact factor: 5.157

6.  Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection.

Authors:  L K Hallak; D Spillmann; P L Collins; M E Peeples
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.

Authors:  L K Hallak; P L Collins; W Knudson; M E Peeples
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

8.  Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans.

Authors:  Isidoro Martínez; José A Melero
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

Review 9.  Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development.

Authors:  A H Brandenburg; H J Neijens; A D Osterhaus
Journal:  Vaccine       Date:  2001-04-06       Impact factor: 3.641

10.  Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein.

Authors:  G P Bembridge; R Garcia-Beato; J A López; J A Melero; G Taylor
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

View more
  22 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Authors:  Yoshihiko Murata; Seana C Catherman
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

3.  Natural history of human respiratory syncytial virus inferred from phylogenetic analysis of the attachment (G) glycoprotein with a 60-nucleotide duplication.

Authors:  Alfonsina Trento; Mariana Viegas; Mónica Galiano; Cristina Videla; Guadalupe Carballal; Alicia S Mistchenko; José A Melero
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Recombinant Sendai viruses expressing fusion proteins with two furin cleavage sites mimic the syncytial and receptor-independent infection properties of respiratory syncytial virus.

Authors:  Joanna Rawling; Olga Cano; Dominique Garcin; Daniel Kolakofsky; José A Melero
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

5.  Inhibition of Human Metapneumovirus Binding to Heparan Sulfate Blocks Infection in Human Lung Cells and Airway Tissues.

Authors:  Edita M Klimyte; Stacy E Smith; Pasqua Oreste; David Lembo; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

6.  Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity.

Authors:  Roberta L Crim; Susette A Audet; Steven A Feldman; Howard S Mostowski; Judy A Beeler
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

7.  Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.

Authors:  Stanislav O Fedechkin; Natasha L George; Ana M Nuñez Castrejon; Joshua R Dillen; Lawrence M Kauvar; Rebecca M DuBois
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

Review 8.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

Review 9.  Structure and function of respiratory syncytial virus surface glycoproteins.

Authors:  Jason S McLellan; William C Ray; Mark E Peeples
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 10.  Viral entry mechanisms: the increasing diversity of paramyxovirus entry.

Authors:  Everett C Smith; Andreea Popa; Andres Chang; Cyril Masante; Rebecca Ellis Dutch
Journal:  FEBS J       Date:  2009-12       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.